Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients

NCT ID: NCT03999411

Last Updated: 2024-03-28

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

39 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-09-09

Study Completion Date

2020-10-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to learn if a mindfulness-based smoking cessation smartphone app can help people quit smoking and stay on antiretroviral therapies.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The current study aims to test the feasibility of a three-arm randomized clinical trial testing the combined mindfulness training + Emocha apps intervention versus the mindfulness training app only with brief advice to improve ART adherence and usual care (UC; brief advice to quit and improve ART adherence). Our primary hypothesis is that the combination of mindfulness training + Emocha apps would be superior to the mindfulness training app with brief advice to improve ART adherence, and these two interventions would be superior to the UC in terms of the feasibility, acceptability, and potential efficacy (3-month smoking cessation; improvement in adherence to ART).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Smoking Smoking Cessation HIV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Usual Care

Participants will receive brief advice to adhere to ART brief advice to quit smoking, 6-week supplies of nicotine-replacement therapy (NRT), and self-help materials to quit smoking and adhere to ART.

Group Type PLACEBO_COMPARATOR

Nicoderm C-Q Transdermal Product

Intervention Type DRUG

6 weeks of GlaxoSmithKline Nicoderm CQ (NRT)

Adherence to Antiretroviral Therapy Counseling

Intervention Type BEHAVIORAL

Brief counseling on adhering to antiretroviral therapy with self-help materials.

Smoking cessation only intervention

Participants in this group will receive the usual care (UC) for adherence to ART, one in-person orientation sessions, 6-week supplies of NRT the "Crave-to-Quit" app, and two brief follow-up phone calls.

Group Type ACTIVE_COMPARATOR

Nicoderm C-Q Transdermal Product

Intervention Type DRUG

6 weeks of GlaxoSmithKline Nicoderm CQ (NRT)

Adherence to Antiretroviral Therapy Counseling

Intervention Type BEHAVIORAL

Brief counseling on adhering to antiretroviral therapy with self-help materials.

Behavioral Smoking Cessation Counseling

Intervention Type BEHAVIORAL

One time face-to-face smoking cessation counseling and 2 follow-up phone calls.

"Crave-to-Quit" app

Intervention Type BEHAVIORAL

Evidence-based mindfulness smoking cessation smartphone app ("Crave-to-Quit") adapted from an in-person mindfulness training relapse prevention smoking cessation intervention.

Combined smoking cessation and HIV intervention

Participants in this group will receive everything given in the Smoking Cessation Only arm and will also use the emocha app and will receive a tutorial explaining the app content and features. The study team will explain to participants that the app will help them in tracking dose-by-dose medication adherence by recording a video for themselves taking their medication.

Group Type EXPERIMENTAL

Nicoderm C-Q Transdermal Product

Intervention Type DRUG

6 weeks of GlaxoSmithKline Nicoderm CQ (NRT)

Adherence to Antiretroviral Therapy Counseling

Intervention Type BEHAVIORAL

Brief counseling on adhering to antiretroviral therapy with self-help materials.

Behavioral Smoking Cessation Counseling

Intervention Type BEHAVIORAL

One time face-to-face smoking cessation counseling and 2 follow-up phone calls.

"Crave-to-Quit" app

Intervention Type BEHAVIORAL

Evidence-based mindfulness smoking cessation smartphone app ("Crave-to-Quit") adapted from an in-person mindfulness training relapse prevention smoking cessation intervention.

vDOT "emocha" app

Intervention Type BEHAVIORAL

Video Directly Observed Therapy (vDOT) smartphone app ("emocha") that allows participants to take a video of themselves taking medication to ensure adherence.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nicoderm C-Q Transdermal Product

6 weeks of GlaxoSmithKline Nicoderm CQ (NRT)

Intervention Type DRUG

Adherence to Antiretroviral Therapy Counseling

Brief counseling on adhering to antiretroviral therapy with self-help materials.

Intervention Type BEHAVIORAL

Behavioral Smoking Cessation Counseling

One time face-to-face smoking cessation counseling and 2 follow-up phone calls.

Intervention Type BEHAVIORAL

"Crave-to-Quit" app

Evidence-based mindfulness smoking cessation smartphone app ("Crave-to-Quit") adapted from an in-person mindfulness training relapse prevention smoking cessation intervention.

Intervention Type BEHAVIORAL

vDOT "emocha" app

Video Directly Observed Therapy (vDOT) smartphone app ("emocha") that allows participants to take a video of themselves taking medication to ensure adherence.

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NRT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥ 18 years old
* Diagnosed with HIV
* Have been prescribed ART medication in the prior 6 months
* Have smoked ≥ 5 cigarettes/day in the past year
* Be interested in making a quit attempt in the next 30 days
* Own a smartphone (apple/android)and plan to keep it active for the following 3 months
* Read/speak English
* Be able to provide consent
* Have no plans to move in the next 3 months
* Not pregnant or planning to be pregnant in the following 3 months

Exclusion Criteria

* Adults unable to consent
* Individuals who are not yet adults (infants, children, teenagers)
* Pregnant women
* Prisoners
* Have contraindication to NRT (past month myocardial infarction, history of serious arrhythmias/or unstable angina pectoris, dermatological disorder)
* Currently being treated for a psychiatric condition
* Currently being treated for smoking cessation, alcoholism, or illicit drug use
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Miami

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Taghrid Asfar

Research Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Taghrid Asfar, MD

Role: PRINCIPAL_INVESTIGATOR

University of Miami

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Miami

Miami, Florida, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20190181

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Learn to Quit-HIV Pilot Study
NCT04609514 COMPLETED NA